DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment

 

 

Oncology Homepage

Varian ARIA, Eclipse and TrueBeam named Category Leaders in the 2018 Best in KLAS: Software and Services Report

Liquid biopsy can help predict outcomes in metastatic triple-negative breast cancer

Provision Healthcare treats first patients using ProNova SC360 proton therapy system

ACA lowered uninsured rate for cancer survivors, study found

Aetna will cover Augmenix's SpaceOAR Hydrogel procedure for men with prostate cancer

Survey shows marginal enrollment increase in radiography educational programs

University of Delaware researchers develop accurate model of how aggressive cancer cells move and spread

U.S. Preventive Services Task Force recommends against screening for ovarian cancer

Europe's first compact proton accelerator arrives in the Netherlands

Median Technologies announces results of deep learning study for enhanced prostate segmentation

Clinical trials and cutting-edge radiation oncology research to be featured at ASTRO’s Annual Meeting in San Diego

Press releases may be edited for formatting or style
The press program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO) will feature advances in cancer research, including reports from phase II and III clinical trials. Studies that examine innovative treatments, such as immunotherapy, mental health influences on cancer outcomes and optimal radiation dosing and sequencing, will also be presented at the largest meeting for the field of radiation oncology.

The meeting, which is expected to attract more than 11,000 attendees, will be held September 24 – 27, 2017, at the San Diego Convention Center. Researchers selected for the press program will share their findings in a series of news briefings held in room 24C and webcast live to registered press (register today!). The schedule is as follows:

Story Continues Below Advertisement

The (#1 Resource) for Medical Imaging and Peripherals. Call 1-949-273-8000

As a Master Distributor for major brands Barco, Philips, and Sony, we offer custom imaging solutions. With our renowned OEM Solutions and Service/Repair Center, Ampronix is a one-stop shop for HD Medical LCD Displays--Printers--Recorders--4K Cameras



The Science of Radiation Oncology: Innovative Approaches
Sunday, September 24, 1:00 – 2:00 p.m. Pacific time

“Consolidative radiotherapy for limited metastatic non-small cell lung cancer: A randomized phase II trial,” Puneeth Iyengar, MD, PhD, University of Texas Southwestern (Abstract LBA-3)
“Phase II 5-arm trial of ipilimumab plus lung or liver stereotactic radiation for patients with advanced malignancies,” James Welsh, MD, MD Anderson Cancer Center (Abstract LBA-5)
“Novel associations between the immune landscape of prostate cancer and post-operative radiation response,” Shuang (George) Zhao, MD, MSE, University of Michigan (Abstract 3)
[invited study to be confirmed]
Moderator: Brian Czito, MD, Duke University
Quality Care in Radiation Oncology: Refining Treatments
Monday, September 25, 11:00 a.m. – 12:00 p.m. Pacific time

“A phase III trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early-stage endometrial cancer: A Gynecology Oncology Group study,” Marcus Randall, MD, FASTRO, University of Kentucky (Abstract LBA-1)
“Two-year results for MC1273, a phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiation in HPV+ oropharynx squamous cell carcinoma (OPSCC),” Daniel Ma, MD, Mayo Clinic (Abstract LBA-14)
“Hypofractionated radiation therapy after mastectomy for the treatment of high-risk breast cancer: Five-year follow-up result of a randomized trial,” Shulian Wang, MD, Chinese Academy of Medical Sciences and Peking Union Medical College (Abstract 5)
“Long-term results of RTOG 0617: A randomized phase III comparison of standard dose versus high dose conformal chemoradiotherapy +/- cetuximab for stage III NSCLC,” Jeffrey Bradley, MD, FASTRO, Washington University at St. Louis (Abstract 227)
  Pages: 1 - 2 - 3 >>

Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED